CEO Increases Stake in Ondine
CEO's trust purchased 200,775 shares at 12p, increasing total holding to 35.3% of issued capital.
- Shares purchased 200,775
- Price per share 12 pence
- Total holding after transaction 156,064,804 Common Shares
- Percentage of issued share capital 35.3057%
Select text to share a quote on X · sign in to keep highlights & notes in your OBI notes
Ondine Biomedical Inc. (AIM: OBI), a Canadian life sciences company pioneering light-activated antimicrobial treatments to treat and prevent multidrug-resistant infections, announces that The Pennycook Family Trust, controlled by Carolyn Cross, CEO, and Robert Cross, husband of Carolyn Cross, has purchased 200,775 shares ("Common Shares") in the Company at a price of 12 pence per Common Share on 30 January 2025.
Following this transaction, Carolyn Cross and Robert Cross, directly and indirectly, hold 156,064,804 Common Shares representing 35.3057% of the issued share capital of the Company.
About Ondine Biomedical Inc.
| 1. | Details of the person discharging managerial responsibilities / person closely associated | |
| a) | Name | Carolyn Cross and her PCA |
| 2. | Reason for the Notification | |
| a) | Position/status | Chief Executive Officer (PDMR) |
| b) | Initial notification/Amendment | Initial notification |
| a) | Name | Ondine Biomedical Inc. |
| b) | LEI | 9845005B69E07CGF4A56 |
| a) | Description of the Financial instrument, type of instrument | Common shares |
| Identification code | ISIN: CA68234M2058 | |
| b) | Nature of the transaction | Share purchase |
| c) | Price(s) and volume(s) | 200,775 shares at 12 pence each |
| d) | Aggregated information: ·Aggregated volume ·Price | N/A |
| e) | Date of the transaction | 30 January 2025 |
| f) | Place of the transaction | AIM |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.